Molecure receives recommendation to continue Phase II trial for OATD-01 in pulmonary sarcoidosis

An independent Data Monitoring Committee has recommended the continuation of the Phase II clinical trial for OATD-01, a dual chitinase inhibitor, following a safety and efficacy review. The trial targets patients with active pulmonary sarcoidosis, a condition with limited therapeutic options. Continued development remains subject to final regulatory and clinical milestones.